Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated, PD-L1-positive, Advanced TNBC By Ogkologos - January 30, 2026 264 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASCENT-04/KEYNOTE-D19 study Source RELATED ARTICLESMORE FROM AUTHOR Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma MOST POPULAR Speaking a thousand words – how a cancer image collection is... September 8, 2021 ¿Vivir cerca de líneas eléctricas aumenta mi riesgo de desarrollar cáncer? February 23, 2023 Mesothelioma Awareness Day: Spotlight on the PrE0506/DREAM3R Clinical Trial September 23, 2021 Final OS and the Exploratory Analysis of the Outcome with Osimertinib... February 13, 2024 Load more HOT NEWS Women in science: Cancer research pioneers – part 1 Mom Who Lost Child Donates Breast Milk To Mom With Cancer EMA Adopts a Positive Opinion for Biosimilar Denosumab Durable Activity of Repotrectinib in Patients with ROS1 Fusion–Positive NSCLC Regardless...
